期刊文献+

新辅助化疗联合保乳手术治疗乳腺癌的临床研究 被引量:1

Clinical research of neoadjuvant chemotherapy combined with breast conserving surgery in the treatment of breast cancer
下载PDF
导出
摘要 目的:探讨新辅助化疗联合保乳手术治疗乳腺癌患者的疗效。方法:收治乳腺癌患者80例,随机分为两组。对照组给予常规乳腺癌根治术治疗,观察组给予新辅助化疗联合保乳术治疗,比较两组疗效。结果:观察组术后平均住院时间、术中出血量、手术耗时明显少于对照组,差异有统计学意义(P<0.05)。观察组术后并发症发生率明显低于对照组,差异有统计学意义(P<0.05)。结论:新辅助化疗联合保乳术治疗乳腺癌患者的临床疗效较好,且安全性较高。 Objective:To investigate the clinical effect of neoadjuvant chemotherapy combined with breast conserving surgery in the treatment of breast cancer.Methods:80 cases of patients with breast cancer were divided into two groups randomly.The control group was treated with conventional radical mastectomy,while the observation group was treated with neoadjuvant chemotherapy combined with breast conserving surgery.The clinical effect between groups was compared.Results:The average hospitalization time,intraoperative blood loss and operative time in the observation group were significantly lower than those in the control group,and the difference was statistically significant(P〈0.05).The incidence of postoperative complications in the observation group was significantly lower than that in the control group,and the difference was statistically significant(P〈0.05).Conclusion:Neoadjuvant chemotherapy combined with breast conserving surgery was effective and safe in the treatment of breast cancer.
作者 陈晶 木拉提.库尔班 赵璐 孙国辉 Chen Jing;Mulati· Kuerban;Zhao Lu;Sun Guohui(Department of Ontology,the Second Hospital Affiliated to Xinjiang Medical Univezsi~v 83006)
出处 《中国社区医师》 2018年第18期15-15,17,共2页 Chinese Community Doctors
基金 新疆医科大学科研创新基金项目(XJC201346)~~
关键词 新辅助化疗 保乳手术 乳腺癌 Neoadjuvant chemotherapy Breast conserving surgery Breast cancer
  • 相关文献

参考文献4

二级参考文献46

  • 1中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2007版)[J].中国癌症杂志,2007,17(5):410-428. 被引量:232
  • 2Asoglu O, Muslumanoglu M, Igci A, et al. Breast conserving surgery after primary chemotherapy in locally advanced breast cancer[J]. Acta Chir Belg, 2005, 105(1):62-68.
  • 3Sethi D, Sen R, Parshad S, et al. Histopathologic changes following neoadjuvant chemotherapy in locally advanced breast cancer[J]. Indian J Cancer, 2013, 50(1):58-64.
  • 4Coudert BP, Largillier R, Arnould L, et al. Multicenter phase I! trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-I trial[J]. J Clin Oncol, 2007, 25(19):2678-2684.
  • 5Gebreamlak EP, Tse GM, Niu Y. Progress in evaluation of pathologic response to neoadjuvant chemotherapy of breast cancer[J]. Anticancer Agents Med Chem, 2013, 13(2):222-226.
  • 6Koolen BB, Vald6s Olmos RA, Elkhuizen PH, et al. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy[J]. Breast Cancer Res Treat, 2012, 135(1):231-240.
  • 7Sanchez-Rovira P, Ant o n A, Bamadas A, et al. Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: results from the GEICAM/2002-01 phase II study[J]. Clin Transl Oncol, 2012, 14(6):430-436.
  • 8Goldhirsch A,Ingie JN,Oelber gD,et aI.Thresholds fortherapies: highlights of the St Gallen International ExpertConsensus on the primary therapy of early breast cancer 2009[J].Ann 0ncol,2009,20(8):1319-1329.
  • 9Bieber A,Brambs HJ,Gabelmann A,et al.Breast MBI formoniuoring response of primary breast cancer to neo-adjuvantchemotherapy[J].Eur Badiol,2002,12(7):1711-1719.
  • 10Costa SD,Loibl S,Kaufmann M,et al.Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data[J].Olin 0ncol,2010,28(1):83-91.

共引文献49

同被引文献7

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部